THE BALANCEhttps://thebalance.clinic/resources/research/mental-health-evidence-2026-q2/

Swiss roots. International expertise. Personal care, delivered with privacy and discretion.

THE BALANCE

Private admissions

Let’s talk about your next step.

Speak with our admissions team about treatment for you or someone you care about.

Privacy and discretion from the first conversation.

Your admissions team

Jil Moore
Jil MooreClient Relations Director
Cynthia Nakhle
Cynthia NakhleAdmissions Manager
Abdullah Boulad, Founder & CEO

Prefer to speak with our founder?

Abdullah Boulad · Swiss entrepreneur · Founder & CEO

Clinical resource

THE BALANCE Quarterly Evidence Briefing: Q2 2026: The Recovery Test Comes Later

A retrospective Q2 2026 briefing on revised drug monitoring, longer-term depression outcomes, Gulf service developments, and withdrawn statistics. The focus is what happens after access and initial treatment.

Clinically reviewed byDr. Sarah Boss, MD
Stone residence with a swimming pool, lawn and palm trees

A positive early result is the beginning of an outcome story. Q2 2026 brought longer-term depression findings, revised English drug monitoring, rehabilitation capacity in Oman, and Qatar’s service results. It also brought a withdrawal of official statistics. Together, these developments asked what remains true after the first appointment, treatment period, or headline.

Key findings

-19% and +54%: reported changes in estimated cocaine and ketamine consumption at sixteen consistently sampled English sites, comparing January through April 2024 with the same months of 2025. [1]

Day eight versus day 365: a small depression trial’s significant early group difference did not remain statistically clear at one year. [2]

30 opened-phase beds and 25 planned beds: capacity described in Oman’s Al Salwa Hospital announcement, not a recovery result. [3]

19,238: calls answered by Qatar’s mental-health helpline in 2025, reported during Q2. Calls are not unique patients or people recovered. [4]

The quarter’s evidence calendar

Releases and corrections during April through June 2026
DateDevelopmentPeriod or status
April 13; June 12 updateHome Office wastewater analysisEarlier observations under revised methods [1]
April 16Oman hospital announcementOpened and planned phases [3]
April 21Qatar helpline report2025 activity [4]
May 15Stockholm depression trial2021 to 2024 trial with one-year follow-up [2]
May 18APMS autism estimates withdrawn2023/24 survey findings removed [5]
June 9European Drug ReportDifferent indicators use different earlier years [6]

England’s drug trends challenged a single European story

The Home Office release contains separate analyses. Experimental national estimates use 42 sites covering 28% of England’s population. The trend comparison uses sixteen sites covering 18%, sampled consistently during January through April. Its revised method superseded the March 2025 figures. [1]

Matched English sites: January through April 2024 and 2025
Substance2024 estimate2025 estimateReported change
Cocaine4,975 ± 2014,045 ± 98-19%
Ketamine691 ± 341,066 ± 30+54%
Heroin1,421 ± 2041,154 ± 271-19%
MDMA257 ± 25311 ± 28+21%
Amphetamine3,311 ± 8331,978 ± 111-40%
Methamphetamine192 ± 8240 ± 8+25%

Units are estimated milligrams consumed per 1,000 people per day under the source’s purity assumptions. The ± values reproduce reported confidence-interval half-widths. These are catchment estimates, not national totals or user counts. [1]

The English cocaine decline can coexist with Q1’s wider European increase because locations, windows, and methods differ. One does not automatically invalidate the other.

For media coverage of financial centers, occupation and wealth remain unmeasured. A catchment’s reputation cannot identify its users. Reporting decreases as well as increases is also essential to an accurate account.

The one-year depression result deserved its own headline

The Stockholm trial randomized 35 adults with recurrent major depression to psilocybin or active placebo, with psychological support in both groups. Its primary day-eight clinician-rated comparison favored active treatment. The day-365 interval included no difference. [2]

Stockholm trial: early and one-year depression-score differencesDay eight: minus 7.27 points, 95 percent interval minus 12.89 to minus 1.65. Day 365: minus 3.68, interval minus 9.30 to plus 1.94. Negative favors psilocybin. Rows show separate visits, not equally spaced time.Between-group MADRS change, 95% confidence intervalsDay 8: primary-7.27Day 365: follow-up-3.68-17-100+4

The later uncertainty does not prove every benefit disappeared or that the true difference is zero. It limits the conclusion at that visit. Source: Yngwe and colleagues. [2]

Two active-group participants experienced persistent severe anxiety requiring medical attention. The study reported no drug-related serious adverse event under its classification. Those statements should remain distinct.

For a time-poor patient, short administration time does not settle the longer care commitment. Ask which period the benefit claim describes and who remains responsible after travel or a return to work.

Oman: capacity opens a pathway, not the outcome analysis

Al Salwa capacity in the April announcementThirty beds in the first phase; twenty-five planned detoxification beds in a second phase. The hollow dashed bar is planned capacity. These are not patients or recovery outcomes. Bars start at zero.Beds described at the April 2026 announcementFirst phase30Planned second phase250102030

Planned beds are not operational capacity. The opening announcement also does not identify the first operating day of every service. Source: Oman Ministry of Health. [3]

The next evaluation should follow assessment, admission, treatment, transfer, and continuing care. A bed count cannot establish those clinical results in advance.

For a family comparing Oman and overseas options, the question is suitability and continuity. Neither location alone predicts the individual’s result.

Qatar: satisfaction was not a recovery measure

Hamad Medical Corporation reported that 90% of anonymous survey respondents were fully satisfied with the helpline, but did not give the survey denominator or response rate in the announcement. That percentage does not describe recovery among all callers. [4]

A person can feel heard and still need treatment. Experience and clinical change both matter, and they need separate measures.

The useful next record would connect advice with referral, attendance, and outcomes under appropriate consent. Repeated contacts should not silently become additional people, and missing follow-up should stay visible.

Europe’s monitoring raised a preparedness question

The European Drug Report identified fifty new psychoactive substances first notified in Europe during 2025. Its June release also described record quantities imported or seized in 2024 and concern about unintended consumption. These are monitoring and enforcement indicators, not treatment-effectiveness measures. [6]

For services, the question is whether assessment considers uncertainty about what was consumed. A familiar substance name is not a complete clinical history.

The report offers no substance-identification guide. Suspected poisoning requires appropriate urgent medical help, not interpretation of a regional trend chart.

Withdrawn numbers should leave the headline

NHS England withdrew its APMS autism findings on May 18, 2026. An August 25 clarification described a data error and assessment-validity limitations preventing a reliable prevalence estimate. The later explanation is identified here as an October preparation note, not Q2 news. [5]

How changed evidence affects this briefing
ChangeTreatment
Revised methodKeep the corrected series internally consistent
Withdrawn estimateExclude it from findings and charts
Later clarificationIdentify it as later information
Missing client-group evidenceDo not substitute national findings for HNW results

A source’s authority does not eliminate the need to check its status. The same correction standard should apply to private providers’ outcome claims.

What this means for private and international care

Ask for the clinical question, evidence, comparator, and follow-up behind a promise. An admissions discussion should explain both the intensive period and the transition home.

The selected findings are directly connected to England, European monitoring, Sweden, Oman, and Qatar. They inform decisions elsewhere without creating a new national score for the USA, Germany, Switzerland, the Netherlands, or every GCC country.

A provider should also explain when inadequate progress or an adverse experience changes the plan. Greater financial resources do not make uncertainty irrelevant. These questions apply to THE BALANCE as well as other services.

The bottom line

Follow the result past the initial headline. Q2 showed why local trends, later outcomes, and source corrections can change a story. Appropriate care needs the right denominator, a relevant period, and a clear next step when the first approach is insufficient.

For journalists

Reporting window: April 1 through June 30, 2026. Prepared retrospectively in October 2026, without backdating.

Key contrast: revised local drug trends, one-year treatment uncertainty, and Gulf access developments require different outcome questions.

Suggested attribution: THE BALANCE retrospective analysis of Q2 official releases and clinical research.

Methodology and sources

This selective narrative briefing includes releases or material changes during Q2. Later clarification is labeled. Original populations, periods, and uncertainty are preserved; no HNW survey, provider ranking, or proprietary outcome is claimed.

  1. Home Office. Wastewater analysis. April 13, 2026; updated June 12.
  2. Yngwe and colleagues. Short- and late-term psilocybin effects. May 15, 2026.
  3. Oman Ministry of Health. Al Salwa Hospital announcement. April 16, 2026.
  4. HMC. Helpline annual activity. April 21, 2026.
  5. NHS England. Autism findings withdrawn May 18; clarification August 25, 2026.
  6. EUDA. New psychoactive substances. European Drug Report, June 9, 2026.
What this includes
01

Clinical context

Clear information is framed around complex and co-occurring presentations.

02

Individual factors

Assessment remains essential because needs and risks differ from person to person.

03

Next steps

A confidential conversation can help clarify the most appropriate route forward.

Not sure where the situation fits?

Your admissions team

Jil Moore
Jil MooreClient Relations Director
Cynthia Nakhle
Cynthia NakhleAdmissions Manager

A confidential first conversation can help clarify the presentation and whether our setting is appropriate.

THE BALANCE
A PLACE TO BEGIN

Ask about our care